€13.63
Your prediction
Arrowhead Pharmaceuticals Inc. Stock
Pros and Cons of Arrowhead Pharmaceuticals Inc. in the next few years
Pros
Cons
Performance of Arrowhead Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Arrowhead Pharmaceuticals Inc. | -2.640% | -7.564% | -0.220% | -44.793% | -26.331% | -49.853% | -53.146% |
| Ironwood Pharmaceuticals | -10.320% | 14.837% | -7.377% | -89.820% | -86.548% | -94.909% | -93.025% |
| Novocure Ltd | 4.200% | 9.318% | -3.023% | -21.596% | -46.016% | -73.835% | -72.285% |
| Iovance Biotherapeutics Inc. | -3.050% | 8.314% | 21.868% | -75.162% | -71.853% | -73.633% | -92.589% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.The financials of Arrowhead Pharma (ARWR) present a complex picture, characterized by significant challenges yet also highlighting potential growth opportunities. While the company operates within the promising biotechnology and medical research sector, its current financial metrics indicate considerable struggles, particularly in generating consistent revenue and maintaining profitability. A detailed analysis reveals both strengths and weaknesses that are important for stakeholders to consider.
Market Capitalization: Arrowhead Pharma boasts a substantial market capitalization of approximately $3.28 billion. This metric not only reflects investor confidence but also indicates that the company has a solid market presence, positioning it well for potential growth and investment opportunities.
Strong Revenue Generation Potential: With total revenue reported at around $35.47 million in the trailing twelve months (TTM), the company shows it can generate income, albeit at low levels relative to its operational costs. There is room for recovery as the company continues to explore its product pipeline.
Comments
